MK-6837 has been discontinued, the company discloses.
ApexOnco Front Page
Recent articles
A US advisory committee votes against camizestrant, but does endorse a new use for Truqap.
Linker-MM4 data raise more questions about sequencing of therapies for multiple myeloma.
Pfizer reveals the discontinuation of PF-08046044.
The company might have blown Enliven out of the water.
The company will try to get the Komzifti QTc prolongation warning removed.
On efficacy, at least, BeOne’s BTK degrader shows an edge.
The first stage of Preserve-003 shows a survival benefit in post-PD-(L)1 lung cancer – with caveats.
